Danaher Corporation (NYSE: DHR) is a global leader in science and technology innovation, headquartered in Washington, D.C. Founded in 1984, the company focuses on life sciences and diagnostics, aiming to address critical global health challenges through strategic acquisitions and integration.
The cornerstone of Danaher’s success is the Danaher Business System (DBS), a proprietary framework centered on continuous improvement, operational efficiency, and innovation. The company operates primarily across three platforms: life sciences, diagnostics, and biotechnology. It provides essential research tools, analytical instruments, reagents, and diagnostic solutions to biopharmaceutical companies, academic institutions, and clinical laboratories. By acquiring key players like Cytiva, Aldevron, and Abcam, Danaher has significantly strengthened its position in gene therapy and drug development, establishing itself as a pivotal supplier in the healthcare industry.
Here are some articles to give you a basic understanding of the company:
Danaher – background and history
Below is a list of articles for the company:
-
Danaher – 2026Q1 results
The following is the summary of Danaher’s (DHR) Q1 2026 earnings report: Financial Highlights Key Business and Market Developments Financial Outlook For the upcoming quarter (Q2 2026), Danaher’s growth momentum is primarily driven by the recovery in bioprocessing and stable improvements in end markets across its business segments. Here is a summary of the key…
-
Danaher – History and Competitions
The history of Danaher can be categorized into four distinct phases, illustrating its evolution from an industrial conglomerate to a pure-play life sciences and diagnostics powerhouse: 1. Origins and Expansion (1969-1984) The roots of Danaher trace back to 1969 with the formation of a real estate investment trust called DMG. In 1984, brothers Steven and…